JP2007501270A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007501270A5 JP2007501270A5 JP2006532213A JP2006532213A JP2007501270A5 JP 2007501270 A5 JP2007501270 A5 JP 2007501270A5 JP 2006532213 A JP2006532213 A JP 2006532213A JP 2006532213 A JP2006532213 A JP 2006532213A JP 2007501270 A5 JP2007501270 A5 JP 2007501270A5
- Authority
- JP
- Japan
- Prior art keywords
- present
- alkyl
- unsubstituted
- represent
- hydrogen atom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0312321A GB0312321D0 (en) | 2003-05-29 | 2003-05-29 | New combination |
| SE0301655A SE0301655D0 (sv) | 2003-06-05 | 2003-06-05 | New combination |
| PCT/SE2004/000817 WO2004105798A1 (en) | 2003-05-29 | 2004-05-27 | A PHARMACEUTICAL COMPOSITION COMPRISING A P2X7-RECEPTOR ANTAGONIST AND A TUMOUR NECROSIS FACTOR α |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007501270A JP2007501270A (ja) | 2007-01-25 |
| JP2007501270A5 true JP2007501270A5 (enExample) | 2007-06-28 |
Family
ID=33492248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006532213A Pending JP2007501270A (ja) | 2003-05-29 | 2004-05-27 | Ｐ２Ｘ７受容体アンタゴニストおよび腫瘍壊死因子αを含む医薬組成物 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20070032465A1 (enExample) |
| EP (1) | EP1633401A1 (enExample) |
| JP (1) | JP2007501270A (enExample) |
| KR (1) | KR20060037258A (enExample) |
| AR (1) | AR044452A1 (enExample) |
| BR (1) | BRPI0410739A (enExample) |
| CA (1) | CA2526883A1 (enExample) |
| CO (1) | CO5640094A2 (enExample) |
| IS (1) | IS8188A (enExample) |
| MX (1) | MXPA05012705A (enExample) |
| NO (1) | NO20056131L (enExample) |
| RU (1) | RU2350354C2 (enExample) |
| TW (1) | TW200507829A (enExample) |
| UY (1) | UY28335A1 (enExample) |
| WO (1) | WO2004105798A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0200920D0 (sv) * | 2002-03-25 | 2002-03-25 | Astrazeneca Ab | Novel compounds |
| SE0300480D0 (sv) | 2003-02-21 | 2003-02-21 | Astrazeneca Ab | Novel compounds |
| US20070281931A1 (en) * | 2003-05-29 | 2007-12-06 | Nigel Boughton-Smith | Pharmaceutical Composition Containing a P2x7 Receptor Antagonist and Methotrexate |
| EP1644041A1 (en) * | 2003-05-29 | 2006-04-12 | AstraZeneca AB | A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine |
| SE0302192D0 (sv) * | 2003-08-08 | 2003-08-08 | Astrazeneca Ab | Novel compounds |
| SE0302488D0 (sv) * | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | New combination |
| SA05260265A (ar) * | 2004-08-30 | 2005-12-03 | استرازينيكا ايه بي | مركبات جديدة |
| SE0402925D0 (sv) * | 2004-11-30 | 2004-11-30 | Astrazeneca Ab | Novel Compounds |
| US20090042832A1 (en) * | 2005-03-07 | 2009-02-12 | Ganga Raju Gokaraju | Novel salts of boswellic acids and selectively enriched boswellic acids and processes for the same |
| GB0919594D0 (en) | 2009-11-09 | 2009-12-23 | Glaxo Group Ltd | Compounds |
| US20130195919A1 (en) | 2010-03-05 | 2013-08-01 | President And Fellows Of Harvard College | Induced dendritic cell compositions and uses thereof |
| US10444122B2 (en) | 2010-04-01 | 2019-10-15 | Agri-Labs Holdings Llc | Soil sample tracking system and method |
| US9538710B2 (en) | 2010-04-01 | 2017-01-10 | Tony Wayne Covely | Crop product tracking system and method |
| EP2739281A1 (en) * | 2011-08-04 | 2014-06-11 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Treatment and prevention of diseases mediated by microorganisms via drug-mediated manipulation of the eicosanoid balance |
| US20130309226A1 (en) | 2012-05-18 | 2013-11-21 | Genentech, Inc. | High-concentration monoclonal antibody formulations |
| KR102035463B1 (ko) * | 2018-02-14 | 2019-11-26 | 연세대학교 산학협력단 | 암 줄기세포의 치료용 약학 조성물 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3471491A (en) * | 1967-08-28 | 1969-10-07 | Squibb & Sons Inc | Adamantyl-s-triazines |
| US3464998A (en) * | 1968-03-04 | 1969-09-02 | Searle & Co | Adamantyl esters and amides of pyridinecarboxylic acids |
| US4349552A (en) * | 1978-10-30 | 1982-09-14 | Fujisawa Pharmaceutical Company, Ltd. | 5-Fluorouracil derivatives, and their pharmaceutical compositions |
| US4751292A (en) * | 1985-07-02 | 1988-06-14 | The Plant Cell Research Institute, Inc. | Adamantyl purines |
| US5399564A (en) * | 1991-09-03 | 1995-03-21 | Dowelanco | N-(4-pyridyl or 4-quinolinyl) arylacetamide and 4-(aralkoxy or aralkylamino) pyridine pesticides |
| IL126557A (en) * | 1996-05-20 | 2002-09-12 | Darwin Discovery Ltd | Quinoline (thio) carboxamides inhibiting TNF or PDE-IV and pharmaceutical preparations containing them |
| SE9704545D0 (sv) * | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| SE9704544D0 (sv) * | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| SK13422001A3 (sk) * | 1999-04-09 | 2002-05-09 | Astrazeneca Ab | Adamantánové deriváty |
| SE9904505D0 (sv) * | 1999-12-09 | 1999-12-09 | Astra Pharma Prod | Novel compounds |
| TWI258462B (en) * | 1999-12-17 | 2006-07-21 | Astrazeneca Ab | Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same |
| GB0013737D0 (en) * | 2000-06-07 | 2000-07-26 | Astrazeneca Ab | Novel compounds |
| NZ530198A (en) * | 2001-07-02 | 2005-11-25 | Akzo Nobel Nv | Tetrahydroquinoline derivatives |
| WO2003042190A1 (en) * | 2001-11-12 | 2003-05-22 | Pfizer Products Inc. | N-alkyl-adamantyl derivatives as p2x7-receptor antagonists |
| PA8557501A1 (es) * | 2001-11-12 | 2003-06-30 | Pfizer Prod Inc | Benzamida, heteroarilamida y amidas inversas |
| SE0103836D0 (sv) * | 2001-11-16 | 2001-11-16 | Astrazeneca Ab | Novel compounds |
| US6908939B2 (en) * | 2001-12-21 | 2005-06-21 | Galderma Research & Development S.N.C. | Biaromatic ligand activators of PPARγ receptors |
| SE0200920D0 (sv) * | 2002-03-25 | 2002-03-25 | Astrazeneca Ab | Novel compounds |
| SE0300445D0 (sv) * | 2003-02-18 | 2003-02-18 | Astrazeneca Ab | New combination |
| SE0300480D0 (sv) * | 2003-02-21 | 2003-02-21 | Astrazeneca Ab | Novel compounds |
| US20070281931A1 (en) * | 2003-05-29 | 2007-12-06 | Nigel Boughton-Smith | Pharmaceutical Composition Containing a P2x7 Receptor Antagonist and Methotrexate |
| EP1644041A1 (en) * | 2003-05-29 | 2006-04-12 | AstraZeneca AB | A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine |
| SE0302192D0 (sv) * | 2003-08-08 | 2003-08-08 | Astrazeneca Ab | Novel compounds |
| SE0302488D0 (sv) * | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | New combination |
-
2004
- 2004-05-27 RU RU2005136131/15A patent/RU2350354C2/ru not_active IP Right Cessation
- 2004-05-27 JP JP2006532213A patent/JP2007501270A/ja active Pending
- 2004-05-27 WO PCT/SE2004/000817 patent/WO2004105798A1/en not_active Ceased
- 2004-05-27 MX MXPA05012705A patent/MXPA05012705A/es not_active Application Discontinuation
- 2004-05-27 CA CA002526883A patent/CA2526883A1/en not_active Abandoned
- 2004-05-27 US US10/558,354 patent/US20070032465A1/en not_active Abandoned
- 2004-05-27 EP EP04735147A patent/EP1633401A1/en not_active Withdrawn
- 2004-05-27 BR BRPI0410739-0A patent/BRPI0410739A/pt not_active IP Right Cessation
- 2004-05-27 KR KR1020057022669A patent/KR20060037258A/ko not_active Ceased
- 2004-05-27 TW TW093115142A patent/TW200507829A/zh unknown
- 2004-05-28 UY UY28335A patent/UY28335A1/es unknown
- 2004-05-28 AR ARP040101848A patent/AR044452A1/es unknown
-
2005
- 2005-11-24 CO CO05119402A patent/CO5640094A2/es not_active Application Discontinuation
- 2005-12-20 IS IS8188A patent/IS8188A/is unknown
- 2005-12-22 NO NO20056131A patent/NO20056131L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007501270A5 (enExample) | ||
| JP2007508360A5 (enExample) | ||
| WO2006023460A3 (en) | COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | |
| IL181095A0 (en) | Polysulfated glycosides and salts thereof | |
| JP2006182786A5 (enExample) | ||
| JP2007519649A5 (enExample) | ||
| WO2004094388A3 (en) | Indazole derivatives as jnk inhibitors | |
| EP1857457A3 (en) | Benzimidazole derivative and its use as AII receptor antagonist | |
| NO20064065L (no) | Diaminopyrimidiner som P2X3 og P2X2/3 antagonister | |
| ATE384058T1 (de) | Thiazolderivate | |
| SE0403006D0 (sv) | New compounds | |
| CA2679198A1 (en) | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases | |
| IL184116A0 (en) | Use of thiazolidinone derivatives as antiangiogenic agents | |
| RU2011147186A (ru) | 2, 5-дизамещенные арилсульфонамидные антагонисты ссr3 | |
| JP2015502371A5 (enExample) | ||
| FI3827829T3 (fi) | Ei-alkoholiperäisen rasvamaksan ehkäisyssä tai hoidossa käytettävä lääkekoostumus, joka sisältää vaikuttavana aineena gpr119-ligandin | |
| WO2007039781A3 (en) | 1,2,4-oxadioi.e derivatives with activity at the metabotropic clutamate receptors | |
| JP2009501745A5 (enExample) | ||
| JP2013531073A5 (enExample) | ||
| CN110612286A (zh) | 氰基取代的稠合双环衍生物及其制备方法和用途 | |
| JP2010513489A5 (enExample) | ||
| EA200700103A1 (ru) | НОВЫЕ 2-ЗАМЕЩЁННЫЕ D-ГОМО-ЭСТРА-1,3,5(10)-ТРИЕНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ 17β-ГИДРОКСИСТЕРОИДДЕГИДРОГЕНАЗЫ ТИПА 1 | |
| WO2018217139A4 (ru) | Новые ингибиторы глутаминилциклаз и их применение для лечения различных заболеваний | |
| JP2006510659A5 (enExample) | ||
| WO2007002764A3 (en) | Di-substituted oxadiazoles as cxc-chemokine receptor ligands |